Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



From the monthly archives: December, 2017

We are pleased to present below all posts archived in 'December, 2017'. If you still can't find what you are looking for, try using the search box.

Highly Efficient Substrate for Culturing ES/iPS Cells

AMSBIO announces iMatrix recombinant Laminin-511 E8 fragments, an innovative cell culture matrix compatible with a wide variety of cell types, and exceptionally well suited for pluripotent stem cells.

Read the rest of entry »

Sanifit appoints Alexander M. Gold, M.D., F.A.C.C. as Chief Medical Officer and President of its US subsidiary

Former SVP and Head of Clinical Development at Portola Pharmaceuticals appointed as Chief Medical Officer

Read the rest of entry »

PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus.

Read the rest of entry »

Exscientia Appoints Alex Snow, Founder of Oxford Innovation Sciences and Former CEO of Lansdowne Partners, as Deputy Chairman

Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.

Read the rest of entry »

Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, today announces that it has been informed by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) that IMCgp100 has been granted Promising Innovative Medicines (PIM) designation for the treatment of patients with metastatic uveal melanoma.

Read the rest of entry »

Global Business Accelerator Programme Cell and Gene Therapy - Innovate UK organising visit to Japan

The Enterprise Europe Network (EEN), in partnership with Innovate UK is organising a funded Accelerator Programme visit to Japan for innovative UK companies operating in the Cell and Gene Therapy sector.

Read the rest of entry »

Leading biotech Immunocore expands to The Oxford Science Park

Oxford, UK:  Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, has taken laboratory and office space at The Oxford Science Park. In its new premises on the Park, Immunocore will be focused on the development of immunotherapies for infectious diseases, complementing its cancer research at Milton Park in Oxford

Read the rest of entry »

Wessex Academic Health Science Network and Wessex Clinical Research Network launch their Technology Support Programme (Round 1)

Wessex Clinical Research Network (CRN) and Wessex Academic Health Science Network (AHSN) have teamed up to support commercial innovators gather crucial evidence on their products.  Their new Technology Support Programme (TSP) will help companies to access the NHS’s research infrastructure to obtain high quality evidence on the economic and health gains their products can bring.

Read the rest of entry »

Arecor Announces Successful Vaccine Stabilising Formulation Technology to More Effectively Combat Two Major Diseases of Livestock in the Developing World

Arecor and its partner, non-profit company, Global Alliance for Livestock Veterinary Medicines (GALVmed), have successfully stabilised liquid formulations of vaccines to combat two major diseases of livestock across the developing world including Africa, Asia and the Middle East In this work, the ArestatTM technology has been applied to enable a vaccine to be distributed pre-prepared in a liquid format without the requirement for in-field reconstitution from the freeze-dried powder form ArestatTM technology has also been applied to reduce the cost of a batch of vaccine diluent by 96 per cent., thereby improving its distribution and uptake by farmers Arecor’s formulation technology work has been supported by Innovate UK through UK aid of the UK government and the Bill & Melinda Gates Foundation Cambridge, UK., 8th December 2017: Arecor Ltd (“the Company”),  a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology ...

Read the rest of entry »

Oxford MEStar wins grant support to work with CGT Catapult and AK Biomedical as part of Jiangsu-UK industrial challenge programme

Oxford MESTar, in collaboration with the Cell and Gene Therapy Catapult and AK Biomedical, has won a grant from Innovate UK to support the development of a novel manufacturing system intended to dramatically reduce the cost of production of CAR-T therapies.

Read the rest of entry »

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.